Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
James Dean Watson currently holds 14,725 shares of Scribe Therapeutics, Inc. (SCTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, James Dean Watson has been a net neutral trader of SCTX stock. They have purchased $0 and sold $0 worth of shares.
James Dean Watson's most recent insider trade was on Jul 23, 2026, when they sold 14,725 shares at $0.00 per share.
James Dean Watson serves as Executive at Scribe Therapeutics, Inc. (SCTX). They have executed 1 insider transactions totaling $0 over their tenure at the company.
James Dean Watson holds the position of Executive at Scribe Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 1 years and currently hold a stake valued at $0.
James Dean Watson has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by James Dean Watson was on Jul 23, 2026, when they purchased $0 worth of SCTX shares. This transaction involved 14,725 shares at N/A per share.
James Dean Watson currently owns 14,725 shares of Scribe Therapeutics, Inc. (SCTX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of James Dean Watson's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. James Dean Watson has 1 Form 4 filings on record as an insider at Scribe Therapeutics, Inc..
Set alerts for James Dean Watson and 40,000+ other insiders.